Literature DB >> 15668888

High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.

Kok-Lung Chan1, Xin-Yuan Guan, Irene Oi-Lin Ng.   

Abstract

Amplification of 8q23-qter is common in human hepatocellular carcinoma (HCC). c-myc, an oncogene located on 8q24, may be important in hepatocarcinogenesis. The present study aimed to evaluate c-myc activation in hepatocarcinogenesis and its clinicopathological significance. High-throughput analysis of c-myc gene amplification and expression using dual-color fluorescence in situ hybridization and immunohistochemistry was performed on tissue microarrays consisting of 458 liver samples comprising HCCs, nontumorous livers and normal livers. HCCs demonstrated frequent c-myc amplification (30% when corrected for chromosome 8 aneusomy). In contrast, the noncancerous livers, which were mostly chronic hepatitis and cirrhosis, exhibited no c-myc amplification. Despite c-myc amplification, the HCCs exhibited less nuclear c-myc expression than the livers with chronic liver diseases and normal livers (P <0.001 and 0.004, respectively). The HCCs also had less cytoplasmic c-myc staining than the livers with chronic liver diseases (P = 0.002). Despite their absence of c-myc amplification, however, the livers with chronic disease had significantly increased expression of both nuclear and cytoplasmic c-myc protein compared with normal livers (P = 0.015 and 0.009, respectively). Clinicopathologically, the reduction in nuclear c-myc was more marked in HCCs with venous permeation and absence of tumor encapsulation (P = 0.013 and 0.021, respectively), whereas HCCs with cytoplasmic c-myc were positively associated with larger tumor size (P = 0.027). There was no significant association between c-myc amplification and protein expression levels in HCC. Our results suggest that overexpression of c-myc in chronic liver diseases may play an important role in the predisposition to hepatocarcinogenesis. Although c-myc was amplified in HCC, there appears to be a tight regulation by independent pathways of c-myc activation in hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15668888     DOI: 10.1016/j.humpath.2004.06.012

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  28 in total

1.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Authors:  Catherine M Shachaf; Andrew J Gentles; Sailaja Elchuri; Debashis Sahoo; Yoav Soen; Orr Sharpe; Omar D Perez; Maria Chang; Dennis Mitchel; William H Robinson; David Dill; Garry P Nolan; Sylvia K Plevritis; Dean W Felsher
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

2.  Lipopolysaccharide stimulates endogenous β-glucuronidase via PKC/NF-κB/c-myc signaling cascade: a possible factor in hepatolithiasis formation.

Authors:  Dianbo Yao; Qianze Dong; Yu Tian; Chaoliu Dai; Shuodong Wu
Journal:  Mol Cell Biochem       Date:  2017-11-29       Impact factor: 3.396

3.  Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice.

Authors:  Jyoti Srivastava; Ayesha Siddiq; Rachel Gredler; Xue-Ning Shen; Devaraja Rajasekaran; Chadia L Robertson; Mark A Subler; Jolene J Windle; Catherine I Dumur; Nitai D Mukhopadhyay; Dawn Garcia; Zhao Lai; Yidong Chen; Uthra Balaji; Paul B Fisher; Devanand Sarkar
Journal:  Hepatology       Date:  2015-01-23       Impact factor: 17.425

4.  Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.

Authors:  Nicola Personeni; Lorenza Rimassa; Tiziana Pressiani; Annarita Destro; Claudia Ligorio; Maria Chiara Tronconi; Silvia Bozzarelli; Carlo Carnaghi; Luca Di Tommaso; Laura Giordano; Massimo Roncalli; Armando Santoro
Journal:  J Cancer Res Clin Oncol       Date:  2013-04-09       Impact factor: 4.553

5.  MicroRNA-based screens for synthetic lethal interactions with c-Myc.

Authors:  Youjun Li; Yahui Zhu; Edward V Prochownik
Journal:  RNA Dis       Date:  2016-05-30

6.  Oncogenic Activation of the RNA Binding Protein NELFE and MYC Signaling in Hepatocellular Carcinoma.

Authors:  Hien Dang; Atsushi Takai; Marshonna Forgues; Yotsowat Pomyen; Haiwei Mou; Wen Xue; Debashish Ray; Kevin C H Ha; Quaid D Morris; Timothy R Hughes; Xin Wei Wang
Journal:  Cancer Cell       Date:  2017-07-10       Impact factor: 31.743

7.  Targeting c-Myc as a novel approach for hepatocellular carcinoma.

Authors:  Che-Pin Lin; Chien-Ru Liu; Chun-Nin Lee; Tze-Sian Chan; H Eugene Liu
Journal:  World J Hepatol       Date:  2010-01-27

8.  Associations between variants of the 8q24 chromosome and nine smoking-related cancer sites.

Authors:  Sungshim Lani Park; Shen-Chih Chang; Lin Cai; Carlos Cordon-Cardo; Bao-Guo Ding; Sander Greenland; Shehnaz K Hussain; Qingwu Jiang; Simin Liu; Ming-Lan Lu; Jenny T Mao; Hal Morgenstern; Li-Na Mu; Leslie J Ng; Allan Pantuck; Jianyu Rao; Victor E Reuter; Donald P Tashkin; Nai-Chieh Y You; Can-Qing Yu; Shun-Zhang Yu; Jin-Kou Zhao; Arie Belldegrun; Zuo-Feng Zhang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-11       Impact factor: 4.254

9.  N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly.

Authors:  Cameron J Schweitzer; Fang Zhang; Audrey Boyer; Kristin Valdez; Maggie Cam; T Jake Liang
Journal:  J Virol       Date:  2018-01-02       Impact factor: 5.103

10.  Central role of c-Myc during malignant conversion in human hepatocarcinogenesis.

Authors:  Pal Kaposi-Novak; Louis Libbrecht; Hyun Goo Woo; Yun-Han Lee; Nathaniel C Sears; Cedric Coulouarn; Elizabeth A Conner; Valentina M Factor; Tania Roskams; Snorri S Thorgeirsson
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.